Kelechi C. Ogbonna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kelechi C. Ogbonna has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Krista L. Donohoe
Virginia Commonwealth University School of Pharmacy
2 shared publications - Lauren G. Pamulapati
Virginia Commonwealth University School of Pharmacy, 410 North 12(th) Street, PO BOX 980581, Richmond, VA 23298, United States of America
2 shared publications - Lauren M. Caldas
Virginia Commonwealth University School of Pharmacy
2 shared publications - Rachel A. Koenig
Tompkins-McCaw Library for the Health Sciences, VCU Libraries, Virginia Commonwealth University, 509 North 12th Street, PO Box 980582, Tompkins-McCaw Library, Room 144C, Richmond, VA 23298-0533, United States
2 shared publications - Abigale T. Matulewicz
Virginia Commonwealth University School of Pharmacy, United States
1 shared publication - Alena C. Hampton
Academic Affairs and Student Success, Rehabilitation Counseling, Virginia Commonwealth University, College of Health Professions, 900 E. Leigh Street, P.O. Box 980233, Richmond, VA, United States
1 shared publication
Latest Publications
- 3 January 2024
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 16 (2) , 132-143
Leadership development in health professions
- 3 January 2024
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 16 (2) , 132-143
Leadership development in health professions
- 21 December 2023
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 16 (1) , 1-4
Falling NAPLEX pass rates are cause for concern
- 21 December 2023
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 16 (1) , 1-4
Falling NAPLEX pass rates are cause for concern
- 1 May 2020
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 12 (5) , 489-492
A call to action: Pharmacy students as leaders in encouraging physical activity as a coping strategy to combat student stress
- 1 May 2020
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 12 (5) , 489-492
A call to action: Pharmacy students as leaders in encouraging physical activity as a coping strategy to combat student stress
- 1 April 2020
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 12 (4) , 357-362
Could recruiting former college athletes be the answer to less pharmacy student burnout?
- 1 April 2020
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 12 (4) , 357-362
Could recruiting former college athletes be the answer to less pharmacy student burnout?
- 1 February 2018
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 10 (2) , 195-200
Medical apps used during advanced pharmacy practice experiences
- 1 February 2018
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 10 (2) , 195-200
Medical apps used during advanced pharmacy practice experiences
- Open Access
- 1 June 2015
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 6, 177-184
Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism
Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism Kelechi C Ogbonna, Dave L Dixon Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA Objective: To compare the safety and efficacy of dabigatran to warfarin for the treatment of deep vein thrombosis and pulmonary embolism. Background: Venous thromboembolism (VTE) is a disease comprised of two conditions: deep vein thrombosis and pulmonary embolism. VTE is a major cause of morbidity and mortality worldwide with an annual incidence estimated at 1–3 cases per 1,000 individuals. This incidence increases with age from 0.1 per 1,000 in adolescence to eight per 1,000 in those 80 years of age and older. As the proportion of patients 65 years of age and older expands, the number of patients presenting with VTE will also increase. Anticoagulation remains the cornerstone of VTE treatment. Traditionally, vitamin K antagonists have been used to minimize the risk of thrombus extension and for secondary prevention. Unpredictable pharmacokinetics and pharmacodynamics, routine monitoring, drug–food and drug–drug interactions, and potentially severe adverse events have all been cited as barriers to optimal care. Dabigatran has been proposed as a suitable alternative to warfarin therapy in the treatment of VTE. Therefore, a critical appraisal of dabigatran's safety and efficacy is necessary to determine its role in therapy. Conclusion: Dabigatran remains an alternative to warfarin therapy for the treatment of VTE. However, dabigatran also has distinct disadvantages that warrant consideration. Clinicians must ensure that drug characteristics align with patient characteristics to optimize patient outcomes. Keywords: venous thromboembolism, pulmonary embolisms, venous thrombosis, anticoagulants, warfarin sodium, dabigatran etexilate mesylate
- 1 June 2015
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 6, 177-184
Open AccessCritical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism
Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism Kelechi C Ogbonna, Dave L Dixon Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA Objective: To compare the safety and efficacy of dabigatran to warfarin for the treatment of deep vein thrombosis and pulmonary embolism. Background: Venous thromboembolism (VTE) is a disease comprised of two conditions: deep vein thrombosis and pulmonary embolism. VTE is a major cause of morbidity and mortality worldwide with an annual incidence estimated at 1–3 cases per 1,000 individuals. This incidence increases with age from 0.1 per 1,000 in adolescence to eight per 1,000 in those 80 years of age and older. As the proportion of patients 65 years of age and older expands, the number of patients presenting with VTE will also increase. Anticoagulation remains the cornerstone of VTE treatment. Traditionally, vitamin K antagonists have been used to minimize the risk of thrombus extension and for secondary prevention. Unpredictable pharmacokinetics and pharmacodynamics, routine monitoring, drug–food and drug–drug interactions, and potentially severe adverse events have all been cited as barriers to optimal care. Dabigatran has been proposed as a suitable alternative to warfarin therapy in the treatment of VTE. Therefore, a critical appraisal of dabigatran's safety and efficacy is necessary to determine its role in therapy. Conclusion: Dabigatran remains an alternative to warfarin therapy for the treatment of VTE. However, dabigatran also has distinct disadvantages that warrant consideration. Clinicians must ensure that drug characteristics align with patient characteristics to optimize patient outcomes. Keywords: venous thromboembolism, pulmonary embolisms, venous thrombosis, anticoagulants, warfarin sodium, dabigatran etexilate mesylate
- 1 February 2015
- Published by Elsevier in Clinics in Geriatric Medicine
- Vol. 31 (1) , 17-27
Antidiabetic Medications and Polypharmacy
- 1 February 2015
- Published by Elsevier in Clinics in Geriatric Medicine
- Vol. 31 (1) , 17-27
Antidiabetic Medications and Polypharmacy
- 1 July 2013
- Published by SLACK, Inc. in Journal of Gerontological Nursing
- Vol. 39 (7) , 8-17
Moving Beyond Warfarin—Are We Ready?: A Review of the Efficacy and Safety of Novel Anticoagulant Agents Compared to Warfarin for the Management of Atrial Fibrillation in Older Adults
Geropharmacology Kelechi C. Ogbonna, PharmD, CGP; Kalin M. Clifford, PharmD Atrial fibrillation (AF) is one of the most common cardiac arrhythmias seen in clinical practice. Stroke risk in patients diagnosed with AF increases from 1.5% in the fifth decade of life to 23.5% in patients older than 80, emphasizing the need for effective and appropriate therapies. Over the past 50 years, vitamin K antagonists—namely warfarin (Coumadin®)—have been the mainstay for stroke prevention. The introduction of dabigatran (Pradaxa®), rivaroxaban (Xarelto®), and apixaban (Eliquis®) has caused both patients and providers to question whether better alternatives to warfarin therapy exist. These agents have shown to be at least as effective as warfarin in stroke risk reduction with no need for international normalized ratio monitoring. This review will examine these newer anticoagulant agents’ safety and efficacy and provide clinical considerations for treating older adults with AF. Clinicians with patients unable to tolerate warfarin or with difficulty managing therapy will need to consider patient characteristics, cost, adherence, lack of a reversal agent, and long-term efficacy before prescribing these agents. [Journal of Gerontological Nursing, 39(7), 8–17.] Dr. Ogbonna is Assistant Professor, Geriatrics, Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, and Dr. Clifford is PGY2 Geriatric Pharmacy Practice Resident, University of Maryland School of Pharmacy, Baltimore, Maryland. The authors have disclosed no potential conflicts of interest, financial or otherwise. Address correspondence to Kelechi C. Ogbonna, PharmD, CGP, Assistant Professor, Geriatrics, Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University School of Pharmacy, 410 N. 12th Street, PO Box 980533, Richmond, VA 23298-0533; e-mail: Kcunegbuogbo@vcu.edu. 10.3928/00989134-20130605-01
- 1 July 2013
- Published by SLACK, Inc. in Journal of Gerontological Nursing
- Vol. 39 (7) , 8-17
Moving Beyond Warfarin—Are We Ready?: A Review of the Efficacy and Safety of Novel Anticoagulant Agents Compared to Warfarin for the Management of Atrial Fibrillation in Older Adults
Geropharmacology Kelechi C. Ogbonna, PharmD, CGP; Kalin M. Clifford, PharmD Atrial fibrillation (AF) is one of the most common cardiac arrhythmias seen in clinical practice. Stroke risk in patients diagnosed with AF increases from 1.5% in the fifth decade of life to 23.5% in patients older than 80, emphasizing the need for effective and appropriate therapies. Over the past 50 years, vitamin K antagonists—namely warfarin (Coumadin®)—have been the mainstay for stroke prevention. The introduction of dabigatran (Pradaxa®), rivaroxaban (Xarelto®), and apixaban (Eliquis®) has caused both patients and providers to question whether better alternatives to warfarin therapy exist. These agents have shown to be at least as effective as warfarin in stroke risk reduction with no need for international normalized ratio monitoring. This review will examine these newer anticoagulant agents’ safety and efficacy and provide clinical considerations for treating older adults with AF. Clinicians with patients unable to tolerate warfarin or with difficulty managing therapy will need to consider patient characteristics, cost, adherence, lack of a reversal agent, and long-term efficacy before prescribing these agents. [Journal of Gerontological Nursing, 39(7), 8–17.] Dr. Ogbonna is Assistant Professor, Geriatrics, Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, and Dr. Clifford is PGY2 Geriatric Pharmacy Practice Resident, University of Maryland School of Pharmacy, Baltimore, Maryland. The authors have disclosed no potential conflicts of interest, financial or otherwise. Address correspondence to Kelechi C. Ogbonna, PharmD, CGP, Assistant Professor, Geriatrics, Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University School of Pharmacy, 410 N. 12th Street, PO Box 980533, Richmond, VA 23298-0533; e-mail: Kcunegbuogbo@vcu.edu. 10.3928/00989134-20130605-01
- 17 April 2013
- Published by Springer Nature in Drugs & Aging
- Vol. 30 (7) , 513-525
Risk versus Benefit of Non-Vitamin K Dependent Anticoagulants Compared to Warfarin for the Management of Atrial Fibrillation in the Elderly
The objective of this review was to compare the safety and efficacy of dabigatran, rivaroxaban and apixaban to warfarin for the management of atrial fibrillation (AF) in older adults. The prevalence and incidence of AF increase with age. Approximately 5 % of the United States population over the age of sixty-five years and 10 % over the age of seventy-nine years have AF. AF is associated with increased risk for thromboembolic events. Despite the increasing incidence and prevalence of AF in older adults and the risks of thromboembolic events, clinicians often avoid anticoagulants. Specifically with warfarin, the risk of hemorrhage may outweigh the benefit in stroke risk reduction in certain populations. Aspirin, while safer to use, is not as effective as warfarin in stroke risk reduction. Newer non-vitamin K dependent antithrombotic therapies (e.g. dabigatran, rivaroxaban, and apixaban) are redefining thromboprophylaxis of AF. Dabigatran, rivaroxaban, and apixaban are at least as effective as warfarin in stroke risk reduction. With new mechanisms of action and no need for therapeutic drug monitoring, countless new patients are potential candidates for anticoagulation. However patient adherence, lack of a reversal agent, cost, and other safety concerns remain reasons for caution and careful consideration. Furthermore, older adults exhibited greater adverse effects from these agents across the clinical trials. This review will examine the newer anticoagulants safety and efficacy with particular attention to their role in treating older adults with AF. Alternatives to warfarin therapy now exist for thromboprophylaxis of AF. Whether these agents represent advances in overall safety in older adults remains uncertain. More experience and research are needed before endorsing their widespread use as a replacement for warfarin in the geriatric population.
- 17 April 2013
- Published by Springer Nature in Drugs & Aging
- Vol. 30 (7) , 513-525
Risk versus Benefit of Non-Vitamin K Dependent Anticoagulants Compared to Warfarin for the Management of Atrial Fibrillation in the Elderly
The objective of this review was to compare the safety and efficacy of dabigatran, rivaroxaban and apixaban to warfarin for the management of atrial fibrillation (AF) in older adults. The prevalence and incidence of AF increase with age. Approximately 5 % of the United States population over the age of sixty-five years and 10 % over the age of seventy-nine years have AF. AF is associated with increased risk for thromboembolic events. Despite the increasing incidence and prevalence of AF in older adults and the risks of thromboembolic events, clinicians often avoid anticoagulants. Specifically with warfarin, the risk of hemorrhage may outweigh the benefit in stroke risk reduction in certain populations. Aspirin, while safer to use, is not as effective as warfarin in stroke risk reduction. Newer non-vitamin K dependent antithrombotic therapies (e.g. dabigatran, rivaroxaban, and apixaban) are redefining thromboprophylaxis of AF. Dabigatran, rivaroxaban, and apixaban are at least as effective as warfarin in stroke risk reduction. With new mechanisms of action and no need for therapeutic drug monitoring, countless new patients are potential candidates for anticoagulation. However patient adherence, lack of a reversal agent, cost, and other safety concerns remain reasons for caution and careful consideration. Furthermore, older adults exhibited greater adverse effects from these agents across the clinical trials. This review will examine the newer anticoagulants safety and efficacy with particular attention to their role in treating older adults with AF. Alternatives to warfarin therapy now exist for thromboprophylaxis of AF. Whether these agents represent advances in overall safety in older adults remains uncertain. More experience and research are needed before endorsing their widespread use as a replacement for warfarin in the geriatric population.